Do you incorporate carboplatin into the treatment for triple negative breast cancer?
The GeparSixto, CALGB 40603, and more recently Prospero support doing it; however, it is not currently endorsed by NCCN and the latter Prospero study calls into question its role in BRCA mutated tumors, contradictory to the TnT study results. Based on this information, in which scenario would you consider it?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Warren Alpert Medical School of Brown University
Answered on
In the neoadjuvant setting, I recommend the addition of carboplatin in all patients (unless medically contraindicated) with stage IIA or higher TNBC. There are now 3 randomized studies - CALGB 40603, GeparSixto and BrighTNess - that have demonstrated significantly higher pCR rates with carboplatin t...
Join for free or sign in to see the full answer